<DOC>
	<DOCNO>NCT01789723</DOCNO>
	<brief_summary>The purpose study determine optimal dose schedule Fusilev prevent reduce Mucositis patient Non-Hodgkin 's Lymphoma receive Folotyn treatment .</brief_summary>
	<brief_title>Phase 1 Study Fusilev Prevent Reduce Mucositis Patients With Non-Hodgkin 's Lymphoma Receiving Folotyn</brief_title>
	<detailed_description>This open label , uncontrolled , nonrandomized , multicenter , dose finding , Phase 1 study primarily determine optimal dose schedule Fusilev prevent reduce Folotyn-related Grade 3 high oral Mucositis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>At least 18 year age Patients relapse refractory NHL eligible Folotyn treatment . Patient histologically/cytologically confirm , measurable ( lesion node ≥ 2 cm compute tomography [ CT ] Progressive disease persistent disease least 1 prior treatment ECOG performance status ≤ 2 Adequate hematological , hepatic , renal function Active concurrent malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) Congestive heart failure Uncontrolled hypertension Known human immunodeficiency virus ( HIV ) positive diagnosis Active uncontrolled infection , underlie medical condition , serious illness would impair ability patient receive protocol treatment Major surgery within 14 day enrollment Pregnant breastfeed woman Symptomatic central nervous system ( CNS ) metastases lesion treatment require . Patients receive prophylactic CNS treatment eligible Previous exposure pralatrexate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>